Skip to main content
spacbrain

NewAmsterdam Pharma Company B.V.

Closed (deSPAC)

Health Care · clinical-stage biopharmaceutical company for cardiometabolic

What it is
A private company in health care preparing to list via a SPAC merger. Full profile in progress.
What it’s doing now
Merging with Frazier Lifesciences Acquisition Corp (FLAC) — closed (despac).
What you should know
The deal carries a $250M minimum-cash condition — heavy redemptions can break it.
Profile in progress — we only publish what we can verify in filings, and for this company that work isn’t finished. Identity and deal facts above are current; business detail, financials and peers will appear as the filings are parsed.

What the company says about itself

Web research — not audited

NewAmsterdam Pharma is a company advancing treatments for cardiovascular disease and other lipid-related conditions. They are investigating obicetrapib, an investigational asset based on CETP inhibition, to lower LDL-C and reduce cardiovascular risk. The company has received positive CHMP opinions for Ubeslo and Evlarco.

Markets:
Cardiovascular Disease | Lipid-Related Conditions
Products:
Ubeslo (Obicetrapib Monotherapy) | Evlarco (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) | obicetrapib
What our web check found

[WEB-INTEL 2026-08-26] 6 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Leading institutional investors commit approximately $235 million through an oversubscribed and upsized private investment in public equity (“PIPE”)" [https://ir.newamsterdampharma.com/news-releases/news-release-details/newamsterdam-pharma-holding-bv-and-frazier-lifesciences] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Gross proceeds from the transactions totaled approximately $328 million" [https://forbion.com/news-insights/news/newamsterdam-pharma-debuts-as-publicly-traded-company/] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "premier healthcare institutional investors have committed $235 million through an oversubscribed PIPE led" [https://www.williamblair.com/News/NewAmsterdam-Pharma-and-Frazier-Lifesciences-Acquisition-Transaction] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "boosting obicetrapib development and NASDAQ listing with $470M funding" [https://www.houthoff.com/insights/deals-and-matters/frazier-lifesciences-announces-listing-on-nasdaq-through-business-combination-with-newamsterdam-pharma/] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The shareholders of FLAC approved the transaction on November 15, 2022" [https://ir.newamsterdampharma.com/news-releases/news-release-details/newamsterdam-pharma-debuts-publicly-traded-company-focused] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "On November 15, 2022, FLAC announced that its shareholders voted to approve the proposed business combination with NewAmsterdam" [https://www.lincolninternational.com/transactions/frazier-lifesciences-acquisition-corporation-has-merged-with-newamsterdam-pharma-holding/]

Source: https://www.newamsterdampharma.com/ · captured Aug 26, 2026 · marketing claims are reported as claims, never merged into the filed figures above.

The deal it’s entering

NewAmsterdam Pharma Company B.V. is merging with Frazier Lifesciences Acquisition Corp (FLAC) currently marked Closed (deSPAC).

Headline equity value—
Minimum cash to close$250M

Structure per SEC accession(s) 0001193125-22-264485. How to read these numbers: headline vs effective valuation · what a definitive agreement commits

What exactly is being valued, and at what

Common questions

Is NewAmsterdam Pharma Company B.V. going public?

NewAmsterdam Pharma Company B.V. has an approved merger with the SPAC Frazier Lifesciences Acquisition Corp (FLAC). Deal status: Closed (deSPAC).

Does NewAmsterdam Pharma Company B.V. have revenue?

The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.

Educational content, not investment advice.

Other health care deals